Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
denileukin diftitox + cyclophosphamide + doxorubicin + vincristine + prednisone
- Development stage
- Phase 3
- Lead developer
- Citius Oncology
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a multi-agent combination regimen consisting of **denileukin diftitox**, **cyclophosphamide**, **doxorubicin**, **vincristine**, and **prednisone**. Denileukin diftitox is an interleukin-2 receptor (IL-2R)-targeted recombinant fusion protein combining diphtheria toxin and human interleukin-2, specifically delivering the toxin to IL-2R-expressing cells, leading to inhibition of protein synthesis and cell death. Cyclophosphamide is an alkylating agent that crosslinks DNA, leading to apoptosis. Doxorubicin is an anthracycline antibiotic which intercalates DNA and inhibits topoisomerase II, causing DNA damage. Vincristine is a vinca alkaloid that disrupts microtubule formation, arresting cell division. Prednisone is a synthetic glucocorticoid with anti-inflammatory and cytotoxic effects on lymphoid tissue. This combination has been studied for peripheral T-cell lymphoma and cutaneous T-cell lymphoma, mainly to increase efficacy in advanced or refractory cases by combining immunotoxin-targeted therapy with cytotoxic chemotherapy[2].
- Brand names
- Ontak
- Other names
- Ontak + CHOPdenileukin diftitox plus CHOPDAB389IL-2 + CHOP
02
Targets
DNAGR (Glucocorticoid receptor)IL-2R (Interleukin-2/interleukin-15 receptor complex)TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on denileukin diftitox + cyclophosphamide + doxorubicin + vincristine + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on denileukin diftitox + cyclophosphamide + doxorubicin + vincristine + prednisone.